HRA004979
Title:
Erythrocyte-aPD-1 conjugate modulates the peripheral immune system to suppress cancers with immune checkpoint blockage resistance
Release date:
2025-07-01
Description:
Here, we developed an erythrocyte-anti-PD-1 antibody conjugate or aPD-1-Ery, where FDA-approved Pembrolizumab is covalently linked to erythrocyte membranes.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Disease Study
Disease name:
cervical cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
P-Ery-Group
Contact person:
gao xiaofei
Email:
gaoxiaofei@westlake.edu.cn
Description:
To download and analyze the initial clinical trials, please contact us.
Individuals & samples
Submitter:   gao xiaofei / gaoxiaofei@westlake.edu.cn
Organization:   Westlake University
Submission date:   2023-07-01
Requests:   -